Atezolizumab Plus Bevacizumab Versus Lenvatinib for Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis
The Journal of Clinical Pharmacology · 2024
DOI: 10.1002/jcph.2402 ↗At a glance
Metaanalyse in The Journal of Clinical Pharmacology, 2024. Written by Jinpeng Lu and 3 co-authors. Institution: Department of Hepatobiliary Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China. Major MEDLINE topics: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Carcinoma, Hepatocellular. Cited 5 times so far (Crossref); 32 references.
Abstract (original language)
Hepatocellular carcinoma (HCC) is often diagnosed in advanced stages. Following sorafenib, lenvatinib (LENV) has been approved as a first‐line treatment option for unresectable HCC. In the past few years, at least 9 large‐scale cohort studies have examined the efficacy and safety of LENV compared to atezolizumab plus bevacizumab (ATE/BEV) in unresectable HCC, but there is currently no direct meta‐analysis conducted for a comprehensive consolidation. To provide the most updated meta‐analysis of the clinical efficacy and safety of ATE/BEV versus LENV for patients with unresectable HCC. Our studies comparing the efficacy and safety of ATE/BEV and LENV in unresectable HCC were systematically searched in PubMed, Embase, and Web of Science from inception to February 2023. Outcomes measured were overall survival (OS), progression‐free survival (PFS), mortality, complete response (CR), partial response (PR), objective response rate (ORR), disease control rate (DCR), progressive disease (PD), stable disease (SD), and adverse events (AEs). Seven eligible studies involving 4428 patients (1569 in the ATE/BEV group and 2859 in the LENV group) were included in the narrative synthesis. All baseline characteristics were similar between the 2 groups except for Child‐Pugh class B. Ultimately, our meta‐analysis showed that the LENV group had longer OS and PFS than the ATE/BEV group. Moreover, patients on LENV were more likely to achieve SD, whereas those on ATE/BEV were more likely to achieve PR.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Hepatobiliary Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China.
- Department of Anesthesiology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China.
ORCID profiles: Xinyi Lin, Haiwen Teng, Yansong Zheng
Cite
APA
Lu, J., Lin, X., Teng, H., & Zheng, Y. (2024). Atezolizumab Plus Bevacizumab Versus Lenvatinib for Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.2402
Vancouver
Lu J, Lin X, Teng H, Zheng Y. Atezolizumab Plus Bevacizumab Versus Lenvatinib for Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis. The Journal of Clinical Pharmacology. 2024. doi:10.1002/jcph.2402
BibTeX
@article{Lu2024,
author = {Lu, Jinpeng and Lin, Xinyi and Teng, Haiwen and Zheng, Yansong},
title = {Atezolizumab Plus Bevacizumab Versus Lenvatinib for Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis},
journal = {The Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1002/jcph.2402}
}
EUVIMED